DE69406664T2 - COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODY AGAINST CD44V6 - Google Patents
COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODY AGAINST CD44V6Info
- Publication number
- DE69406664T2 DE69406664T2 DE69406664T DE69406664T DE69406664T2 DE 69406664 T2 DE69406664 T2 DE 69406664T2 DE 69406664 T DE69406664 T DE 69406664T DE 69406664 T DE69406664 T DE 69406664T DE 69406664 T2 DE69406664 T2 DE 69406664T2
- Authority
- DE
- Germany
- Prior art keywords
- cell
- epitope
- cd44v6
- cells
- hermes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
CD44 is a family of glycoproteins involved in cell-cell and cell-matrix interactions. In addition to the major 90 kD form present on most hematopoietic cells, larger forms are found on keratinocytes and carcinoma cell lines. These bigger isoforms of CD44 arise by alternative splicing that results in insertion of one or more of the "variant" exons into the extracellular part of the 90 kD constant form of the molecule. Antibodies were raised against a synthetic peptide containing a sequence encoded by the human exon 6A mAb thus obtained (designated Var3.1) strongly reacted with the plasma membranes of squamous cells in upper layers of skin and tonsil surface epithelia. Weaker staining was seen in germinal centers, vascular endothelia and enterocytes. CD44v6 was absent from tissue leukocytes and connective tissue components. In comparison, Hermes-3 epitope (on the constant part) containing forms of CD44 were preferentially localized in basal layers of epithelia, present on the surface of most leukocytes and connective tissue cells, and undetectable on the luminal surface of high endothelial venules. In benign neoplasms, epithelial cells stained with mAb Var3.1 like in normal tissues. In contrast, immunostaining of 30 squamous carcinoma specimens (both primary and metastatic lesions) revealed that malignant transformation resulted in down-regulation or disappearance of Var3.1 epitope, but in majority of cases, not in diminished expression of the Hermes-3 epitope. An examination of serum samples from normal individuals and from patients with inflammatory diseases indicated that CD44v6 was increased in samples from patients with rheumatoid arthritis or inflammatory bowel disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7806393A | 1993-06-18 | 1993-06-18 | |
PCT/FI1994/000264 WO1995000658A1 (en) | 1993-06-18 | 1994-06-16 | COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69406664D1 DE69406664D1 (en) | 1997-12-11 |
DE69406664T2 true DE69406664T2 (en) | 1998-06-04 |
Family
ID=22141703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69406664T Expired - Fee Related DE69406664T2 (en) | 1993-06-18 | 1994-06-16 | COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODY AGAINST CD44V6 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5616468A (en) |
EP (1) | EP0703989B1 (en) |
JP (1) | JPH08511419A (en) |
AT (1) | ATE159953T1 (en) |
AU (1) | AU678487B2 (en) |
CA (1) | CA2165461A1 (en) |
DE (1) | DE69406664T2 (en) |
DK (1) | DK0703989T3 (en) |
ES (1) | ES2110764T3 (en) |
GR (1) | GR3025759T3 (en) |
IL (1) | IL110070A0 (en) |
WO (1) | WO1995000658A1 (en) |
ZA (1) | ZA944383B (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4134982A1 (en) * | 1991-10-23 | 1993-04-29 | Kernforschungsz Karlsruhe | USE OF ANTIBODY-CONTAINING PREPARATIONS FOR IMMUNE SUPPRESSION |
EP0656906B1 (en) * | 1992-06-09 | 1999-09-08 | Oy Biotie Therapies | A novel endothelial cell molecule mediating lymphocyte binding in man |
UA58482C2 (en) * | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | MONOCLONAL ANTIBODY VFF-18 AGAINST CD44v6 AND ITS FRAGMENTS |
DE19540515C1 (en) * | 1995-10-31 | 1997-02-06 | Boehringer Ingelheim Int | Tumor therapy through adoptive transfer of CD44v-specific cytotoxic T lymphocytes |
DE19545472A1 (en) * | 1995-12-06 | 1997-06-12 | Boehringer Ingelheim Int | Diagnosis of squamous epithelial cell carcinoma |
UY24389A1 (en) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FLAT EPITHELIUM CARCINOMA |
DE19653607A1 (en) | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Int | Procedure for diagnosis and therapy of Hodgkin lymphoma |
US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20050100542A1 (en) * | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8048416B2 (en) * | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20090004103A1 (en) * | 1999-10-08 | 2009-01-01 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7189397B2 (en) * | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US6972324B2 (en) * | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
US8986944B2 (en) | 2001-10-11 | 2015-03-24 | Aviva Biosciences Corporation | Methods and compositions for separating rare cells from fluid samples |
US8980568B2 (en) | 2001-10-11 | 2015-03-17 | Aviva Biosciences Corporation | Methods and compositions for detecting non-hematopoietic cells from a blood sample |
US20040110933A1 (en) * | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
CN102504025B (en) * | 2004-03-10 | 2015-10-21 | 克赖顿大学 | Estrogen receptor and using method |
WO2005095987A2 (en) * | 2004-03-26 | 2005-10-13 | University Of Miami | Salivary soluble cd44: a molecular marker for head and neck cancer |
EP2041299A4 (en) * | 2006-07-14 | 2010-01-13 | Aviva Biosciences Corp | Methods and compositions for detecting rare cells from a biological sample |
US20080057505A1 (en) * | 2006-07-14 | 2008-03-06 | Ping Lin | Methods and compositions for detecting rare cells from a biological sample |
WO2010058396A1 (en) | 2008-11-19 | 2010-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A cd44vra antibody and diagnostic and therapeutic methods using same |
MX2013010910A (en) * | 2011-03-24 | 2014-03-27 | Neurim Pharma 1991 | Neuroprotective peptides. |
RU2017104284A (en) | 2014-07-15 | 2018-08-15 | Йиссум Рисеч Девелопмент Компани Оф Зе Хебрю Юниверсити Оф Джерусалем Лтд. | ISOLATED POLYPEPTIDES CD44 AND THEIR APPLICATION |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4014510A1 (en) | 1990-05-07 | 1991-11-14 | Kernforschungsz Karlsruhe | VARIANT CD44 SURFACE PROTEINS, THESE ENCODING C-DNA SEQUENCES, ANTIBODIES AGAINST THESE PROTEINS AND THEIR USE IN DIAGNOSTICS AND THERAPY |
DE4134982A1 (en) | 1991-10-23 | 1993-04-29 | Kernforschungsz Karlsruhe | USE OF ANTIBODY-CONTAINING PREPARATIONS FOR IMMUNE SUPPRESSION |
-
1994
- 1994-06-16 WO PCT/FI1994/000264 patent/WO1995000658A1/en active IP Right Grant
- 1994-06-16 DK DK94918396.6T patent/DK0703989T3/en active
- 1994-06-16 DE DE69406664T patent/DE69406664T2/en not_active Expired - Fee Related
- 1994-06-16 AT AT94918396T patent/ATE159953T1/en not_active IP Right Cessation
- 1994-06-16 JP JP6523607A patent/JPH08511419A/en not_active Ceased
- 1994-06-16 CA CA002165461A patent/CA2165461A1/en not_active Abandoned
- 1994-06-16 AU AU69726/94A patent/AU678487B2/en not_active Ceased
- 1994-06-16 EP EP94918396A patent/EP0703989B1/en not_active Expired - Lifetime
- 1994-06-16 ES ES94918396T patent/ES2110764T3/en not_active Expired - Lifetime
- 1994-06-20 IL IL11007094A patent/IL110070A0/en unknown
- 1994-06-20 ZA ZA944383A patent/ZA944383B/en unknown
-
1995
- 1995-05-30 US US08/453,378 patent/US5616468A/en not_active Expired - Lifetime
-
1997
- 1997-12-23 GR GR970403410T patent/GR3025759T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2165461A1 (en) | 1995-01-05 |
US5616468A (en) | 1997-04-01 |
WO1995000658A1 (en) | 1995-01-05 |
DK0703989T3 (en) | 1998-02-09 |
GR3025759T3 (en) | 1998-03-31 |
IL110070A0 (en) | 1994-10-07 |
ZA944383B (en) | 1995-03-03 |
JPH08511419A (en) | 1996-12-03 |
AU6972694A (en) | 1995-01-17 |
ES2110764T3 (en) | 1998-02-16 |
EP0703989B1 (en) | 1997-11-05 |
EP0703989A1 (en) | 1996-04-03 |
ATE159953T1 (en) | 1997-11-15 |
DE69406664D1 (en) | 1997-12-11 |
AU678487B2 (en) | 1997-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69406664T2 (en) | COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODY AGAINST CD44V6 | |
Meigel et al. | Dermal architecture and collagen type distribution | |
Bukovský et al. | The localization of Thy-1.1, MRC OX 2 and Ia antigens in the rat ovary and fallopian tube. | |
Fogel et al. | L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma | |
Weiss et al. | An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function | |
Sasaki et al. | Expression and distribution of laminin α1 and α2 chains in embryonic and adult mouse tissues: an immunochemical approach | |
Sappino et al. | Smooth muscle differentiation in scleroderma fibroblastic cells. | |
Purkis et al. | Antibody markers of basal cells in complex epithelia | |
Sheikh et al. | Endo180, an endocytic recycling glycoprotein related to the macrophage mannose receptor is expressed on fibroblasts, endothelial cells and macrophages and functions as a lectin receptor | |
Natali et al. | Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions | |
Matsuura et al. | The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. | |
Heyderman et al. | A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2 | |
Sers et al. | MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread | |
Chaubal et al. | CD34 immunoreactivity in nervous system tumors | |
Hormia et al. | Expression of cytokeratins in odontogenic jaw cysts: monoclonal antibodies reveal distinct variation between different cyst types | |
Hamilton et al. | Characterization of a human endocrine tissue and tumor-associated Ewing's sarcoma antigen | |
Bordessoule et al. | Immunohistological patterns of myeloid antigens: tissue distribution of CD13, CD14, CD16, CD31, CD36, CD65, CD66 and CD67 | |
Cagnano et al. | Expression of ligands to NKp46 in benign and malignant melanocytes | |
Adachi et al. | Microvascular architecture of early gastric carcinoma. Microvascular–histopathologic correlates | |
Posnett et al. | A membrane antigen (HC1) selectively present on hairy cell leukemia cells, endothelial cells, and epidermal basal cells. | |
Tiitta et al. | Tenascin in inflammatory conditions and neoplasms of the urinary bladder | |
Gilcrease et al. | Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas | |
Georgolios et al. | THE ROLE OF CD�� ADHESION MOLECULE IN ORAL CAVITY CANCER | |
Castagna et al. | Mammary cancer antigen recognized by monoclonal antibody B72. 3 in apocrine metaplasia of the human breast | |
Rudland et al. | Characterization of human mammary cell types in primary culture: immunofluorescent and immunocytochemical indicators of cellular heterogeneity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |